CardiaTec raises $6.5M for AI-driven drug discovery in cardiovascular diseases.

Cambridge University's CardiaTec has secured $6.5 million to advance AI-driven drug discovery for cardiovascular diseases (CVDs), which cause 17.9 million deaths annually. The startup is creating the largest human heart tissue multi-omics dataset through partnerships with 65 hospitals in the UK and US. By analyzing complex biological data, CardiaTec aims to uncover novel treatments and enhance understanding of CVD mechanisms.

September 10, 2024
4 Articles

Further Reading